| BDNF: an oncogene or tumor suppressor? DP Radin, P Patel Anticancer research 37 (8), 3983-3990, 2017 | 81 | 2017 |
| Interactions between tumor cells, neurons, and microglia in the glioma microenvironment DP Radin, SE Tsirka International journal of molecular sciences 21 (22), 8476, 2020 | 67 | 2020 |
| Delineating the molecular mechanisms of tamoxifen’s oncolytic actions in estrogen receptor-negative cancers DP Radin, P Patel European journal of pharmacology 781, 173-180, 2016 | 36 | 2016 |
| Lifeguard inhibition of Fas-mediated apoptosis: A possible mechanism for explaining the cisplatin resistance of triple-negative breast cancer cells D Radin, A Lippa, P Patel, D Leonardi Biomedicine & Pharmacotherapy 77, 161-166, 2016 | 30 | 2016 |
| A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors DP Radin, P Patel Biomedicine & Pharmacotherapy 87, 636-639, 2017 | 29 | 2017 |
| PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: Involvement of ROS and mitophagy K Dai, DP Radin, D Leonardi Pharmacological Reports 71 (6), 1184-1189, 2019 | 27 | 2019 |
| A distinct microglial subset at the tumor–stroma interface of glioma MD Caponegro, K Oh, MM Madeira, D Radin, N Sterge, M Tayyab, ... Glia 69 (7), 1767-1781, 2021 | 20 | 2021 |
| Acute ampakine treatment ameliorates age-related deficits in long-term potentiation DP Radin, S Zhong, R Purcell, A Lippa Biomedicine & Pharmacotherapy 84, 806-809, 2016 | 20 | 2016 |
| Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain DP Radin, S Johnson, R Purcell, AS Lippa Biomedicine & Pharmacotherapy 105, 540-544, 2018 | 16 | 2018 |
| Our ACE in the HOLE: justifying the use of angiotensin-converting enzyme inhibitors as adjuvants to standard chemotherapy DP Radin, A Krebs, A Maqsudlu, P Patel Anticancer Research 38 (1), 45-49, 2018 | 16 | 2018 |
| Deciphering the dual role and prognostic potential of PINK1 across cancer types K Dai, DP Radin, D Leonardi Neural regeneration research 16 (4), 659-665, 2021 | 12 | 2021 |
| Probing the oncolytic and chemosensitizing effects of dihydrotanshinone in an in vitro glioblastoma model V Kumar, D Radin, D Leonardi Anticancer Research 37 (11), 6025-6030, 2017 | 11 | 2017 |
| Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier V Kumar, D Radin, D Leonardi Biomedicine & Pharmacotherapy 109, 386-390, 2019 | 10 | 2019 |
| Brain vacuolation resulting from administration of the type II ampakine CX717 is an artifact related to molecular structure and chemical reaction with tissue fixative agents R Purcell, G Lynch, C Gall, S Johnson, Z Sheng, MR Stephen, J Cook, ... Toxicological Sciences 162 (2), 383-395, 2018 | 10 | 2018 |
| Oncolytic properties of ampakines in vitro DP Radin, R Purcell, AS Lippa Anticancer Research 38 (1), 265-269, 2018 | 9 | 2018 |
| Probing the molecular mechanisms governing the oncolytic activity of Paeonia suffruticosa on triple-negative breast cancer cells in vitro D Kim, D Radin, D Leonardi Anticancer Research 37 (9), 4813-4819, 2017 | 9 | 2017 |
| Lucanthone targets lysosomes to perturb glioma proliferation, chemoresistance and stemness, and slows tumor growth in vivo DP Radin, G Smith, V Moushiaveshi, A Wolf, R Bases, SE Tsirka Frontiers in Oncology 12, 852940, 2022 | 8 | 2022 |
| Tarps differentially affect the pharmacology of ampakines DP Radin, YX Li, G Rogers, R Purcell, A Lippa Biochemical Pharmacology 154, 446-451, 2018 | 7 | 2018 |
| From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade glioma GT Smith, DP Radin, SE Tsirka Frontiers in Immunology 13, 958620, 2022 | 6 | 2022 |
| Stargazin differentially modulates ampakine gating kinetics and pharmacology DP Radin, YX Li, G Rogers, R Purcell, A Lippa Biochemical Pharmacology 148, 308-314, 2018 | 5 | 2018 |
